The Global Drug sales of Opdivo stood at USD 9,566.59 Millions in 2022
The indicator recorded a historical growth (CAGR) of6.11% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Nivolumab (Opdivo) is a human IgG4 anti-PD-1 monoclonal antibody. Opdivo is formulated as solution and concentrate solution for intravenous route of administration.
Mechanism of Action
nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Anti-PD-1 human monoclonal antibody MDX-1106 binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.
Opdivo Overview
Opdivo is marketed for the treatment of several indications in Genetic Disorders, Infectious Disease, Mouth and Dental Disorders, and Oncology therapy areas.
Opdivo is indicated for the treatment of unresectable melanoma. Opdivo as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo is indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo in combination with ipilimumab, is indicated for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma. Opdivo is also indicated for the treatment of several other indications including Esophageal Squamous Cell Carcinoma (ESCC), Kidney Cancer (Renal Cell Cancer), Esophageal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Gastric Cancer, and Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary).
Opdivo was first approved in 2014 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Ono Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co. Opdivo drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer